New Research Offers an In-Depth Competitive Landscape Assessment of the Targeted Oncology Market Place.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45675) has announced the addition of "Targeted Therapies in Oncology on co·log i·cal (-k -l j: A World Review "to their offering. The dogma for treatment of cancer has changed, with the cytotoxic drugs used in chemotherapy regimes set to lose their dominance and be used alongside targeted therapies that are being developed with the aim of more specifically targeting cancer cells. Research and analysis highlights -- In this comprehensive report covering targeted therapies in oncology, we have analyzed protein kinase protein kinase /pro·tein ki·nase/ (pro´ten ki´nas) an enzyme that catalyzes the phosphorylation of serine, threonine, or tyrosine groups in enzymes or other proteins, using ATP as a phosphate donor. inhibitors, anti-angiogenic angiogenic /an·gio·gen·ic/ (-jen´ik) 1. pertaining to angiogenesis. 2. of vascular origin. and vascular targeting agents, immunostimulators, antibodies and vaccines in oncology. -- This extensive 410+ page report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the mentioned key oncology targeted therapy areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors. -- The number of targeted therapy drugs has risen sharply, as have the number of targets. The fiercest competition in oncology targeted therapy is pointed out and how several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline. Scope of this report -- In-depth competitive landscape assessment of the targeted oncology market place; Including more than 300 drugs and pharmaceutical companies -- Thorough review of five major targeting strategies in oncology: Protein kinase inhibitors, Anti-angiogenic and vascular targeting agents, Immunostimulators, Antibodies and Vaccines -- Progress analysis of major cancer indications for respective targeting strategy, including players, drugs, clinical progress and pitfalls Key reasons to read this report -- Understand the clinical and strategic challenges to the commercialization of five major targeting strategies in oncology -- Assess opportunities and risks for the continued development of targeting agents in major cancer indications. -- Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development Topics Covered: -- Methodology -- Protein Kinase Inhibitors -- Anti-Angiogenesis & Vascular Targeting -- Immunotherapy in Oncology -- Competitive Landscape in Cancer Vaccines -- Antibody Deals on the Rise -- Tumor Antigens -- Immunomodulators immunomodulator /im·mu·no·mod·u·lat·or/ (-mod´u-la´ter) an agent that augments or diminishes immune responses. & Adjuvants in Cancer Vaccines -- Cancer Vaccine Delivery -- New Approaches in Antibody Delivery and Design - The Next Generation -- Cancer Vaccines in Development: By Major Indications -- Antibodies in Clinical Development -- Company Index -- Drug Index Companies Mentioned: -- Novartis Deals -- AstraZeneca -- Pfizer -- GlaxoSmithKline For more information visit http://www.researchandmarkets.com/reports/c45675 |
|
||||||||||||||

co·log
i·cal
-l
j
Printer friendly
Cite/link
Email
Feedback
Reader Opinion